title: Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
abstract: Chagas disease, caused by the eukaryotic (protozoan) parasite Trypanosoma cruzi, is an alarming emerging global health problem with no clinical drugs available to treat the chronic stage. Azole inhibitors of sterol 14α-demethylase (CYP51) were proven effective against Chagas, and antifungal drugs posaconazole and ravuconazole have entered clinical trials in Spain, Bolivia, and Argentina. Here we present the x-ray structures of T. cruzi CYP51 in complexes with two alternative drug candidates, pyridine derivatives (S)-(4-chlorophenyl)-1-(4-(4-(trifluoromethyl)phenyl)-piperazin-1-yl)-2-(pyridin-3-yl)ethanone (UDO; Protein Data Bank code 3ZG2) and N-[4-(trifluoromethyl)phenyl]-N-[1-[5-(trifluoromethyl)-2-pyridyl]-4-piperi-dyl]pyridin-3-amine (UDD; Protein Data Bank code 3ZG3). These compounds have been developed by the Drugs for Neglected Diseases initiative (DNDi) and are highly promising antichagasic agents in both cellular and in vivo experiments. The binding parameters and inhibitory effects on sterol 14α-demethylase activity in reconstituted enzyme reactions confirmed UDO and UDD as potent and selective T. cruzi CYP51 inhibitors. Comparative analysis of the pyridine- and azole-bound CYP51 structures uncovered the features that make UDO and UDD T. cruzi CYP51-specific. The structures suggest that although a precise fit between the shape of the inhibitor molecules and T. cruzi CYP51 active site topology underlies their high inhibitory potency, a longer coordination bond between the catalytic heme iron and the pyridine nitrogen implies a weaker influence of pyridines on the iron reduction potential, which may be the basis for the observed selectivity of these compounds toward the target enzyme versus other cytochrome P450s, including human drug-metabolizing P450s. These findings may pave the way for the development of novel CYP51-targeted drugs with optimized metabolic properties that are very much needed for the treatment of human infections caused by eukaryotic microbial pathogens.
authors.affiliation: From the Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232.
authors.forename: Tatiana Y
authors.initials: TY
authors.lastname: Hargrove
authors.forename: Zdzislaw
authors.initials: Z
authors.lastname: Wawrzak
authors.forename: Paul W
authors.initials: PW
authors.lastname: Alexander
authors.forename: Jason H
authors.initials: JH
authors.lastname: Chaplin
authors.forename: Martine
authors.initials: M
authors.lastname: Keenan
authors.forename: Susan A
authors.initials: SA
authors.lastname: Charman
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Perez
authors.forename: Michael R
authors.initials: MR
authors.lastname: Waterman
authors.forename: Eric
authors.initials: E
authors.lastname: Chatelain
authors.forename: Galina I
authors.initials: GI
authors.lastname: Lepesheva
mesh_terms: D058888:14-alpha Demethylase Inhibitors / Q000737:chemistry* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000737:chemistry* / Q000627:therapeutic use; D014355:Chagas Disease / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D018360:Crystallography, X-Ray; D006801:Humans; D015800:Protozoan Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D058886:Sterol 14-Demethylase / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D013844:Thiazoles / Q000737:chemistry; D014230:Triazoles / Q000737:chemistry; D014349:Trypanosoma cruzi / Q000201:enzymology* / Q000235:genetics
chemical_list: D058888:14-alpha Demethylase Inhibitors; D000981:Antiprotozoal Agents; D015800:Protozoan Proteins; D013844:Thiazoles; D014230:Triazoles; C101425:posaconazole; C104066:ER 30346; D058886:Sterol 14-Demethylase
keywords: Cytochrome P450; Drug Discovery; Enzyme Inhibitors; Infectious Diseases; Protein Complexes; Protein Structure; Sterol 14α-Demethylase; Trypanosoma cruzi; X-ray Crystallography
references.citation: Biochim Biophys Acta. 2011 Jan;1814(1):88-93
references.pmid: 20547249
references.citation: Mol Biochem Parasitol. 2003 Feb;126(2):129-42
references.pmid: 12615312
references.citation: Antimicrob Agents Chemother. 2000 Jan;44(1):150-5
references.pmid: 10602737
references.citation: Curr Opin Anaesthesiol. 2010 Aug;23(4):441-8
references.pmid: 20610983
references.citation: Mol Pharmacol. 2013 Jul;84(1):86-94
references.pmid: 23604141
references.citation: Antimicrob Agents Chemother. 2013 Sep;57(9):4151-63
references.pmid: 23774435
references.citation: J Biol Chem. 1984 Nov 10;259(21):13402-12
references.pmid: 6208195
references.citation: J Biol Chem. 2011 Jul 29;286(30):26838-48
references.pmid: 21632531
references.citation: Rev Iberoam Micol. 2008 Jun;25(2):101-6
references.pmid: 18473504
references.citation: Org Lett. 2012 Dec 21;14(24):6322-5
references.pmid: 23214987
references.citation: J Infect Dis. 2013 Aug 1;208(3):504-11
references.pmid: 23372180
references.citation: Antimicrob Agents Chemother. 2012 Sep;56(9):4914-21
references.pmid: 22777048
references.citation: J Pharmacol Exp Ther. 2006 Jan;316(1):336-48
references.pmid: 16192315
references.citation: Antimicrob Agents Chemother. 1990 Nov;34(11):2097-105
references.pmid: 2073100
references.citation: J Lipid Res. 1989 Oct;30(10):1621-32
references.pmid: 2614264
references.citation: Nature. 2010 Jun 24;465(7301):S12-5
references.pmid: 20571548
references.citation: Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
references.pmid: 15299374
references.citation: Biochem Biophys Res Commun. 1986 May 14;136(3):851-6
references.pmid: 3521598
references.citation: AAPS J. 2006 Mar 10;8(1):E101-11
references.pmid: 16584116
references.citation: J Biol Chem. 2001 Jul 27;276(30):28413-20
references.pmid: 11373285
references.citation: Chem Biol. 2007 Nov;14(11):1283-93
references.pmid: 18022567
references.citation: Adv Parasitol. 2011;75:65-87
references.pmid: 21820552
references.citation: J Antimicrob Chemother. 2000 Jun;45(6):819-24
references.pmid: 10837436
references.citation: Mol Biochem Parasitol. 1981 Jul;3(3):169-80
references.pmid: 6265775
references.citation: Biochemistry. 2004 Aug 24;43(33):10789-99
references.pmid: 15311940
references.citation: Drug Metab Dispos. 2002 Mar;30(3):314-8
references.pmid: 11854151
references.citation: J Biol Chem. 1964 Jul;239:2370-8
references.pmid: 14209971
references.citation: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2184-95
references.pmid: 15572771
references.citation: J Biol Chem. 2006 Feb 10;281(6):3577-85
references.pmid: 16321980
references.citation: Antimicrob Agents Chemother. 1996 Nov;40(11):2592-7
references.pmid: 8913471
references.citation: Biochemistry. 2003 Aug 5;42(30):9091-101
references.pmid: 12885242
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15149-53
references.pmid: 14657358
references.citation: J Biol Chem. 2012 Jun 1;287(23):19699-714
references.pmid: 22500029
references.citation: Bioorg Med Chem. 2013 Apr 1;21(7):1756-63
references.pmid: 23462713
references.citation: Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:311-8
references.pmid: 19753490
references.citation: Int J Parasitol Drugs Drug Resist. 2012 Dec;2:178-186
references.pmid: 23504044
references.citation: J Mol Biol. 2010 Apr 9;397(4):1067-78
references.pmid: 20149798
references.citation: Drug Metab Rev. 2007;39(2-3):481-99
references.pmid: 17786634
references.citation: J Biol Chem. 2010 Aug 13;285(33):25582-90
references.pmid: 20530488
references.citation: J Med Chem. 2013 Mar 28;56(6):2556-67
references.pmid: 23448316
references.citation: J Biol Chem. 2010 Jan 15;285(3):1773-80
references.pmid: 19923211
references.citation: J Med Chem. 2012 May 10;55(9):4189-204
references.pmid: 22536986
references.citation: Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
references.pmid: 20383002
references.citation: Clin Infect Dis. 2008 Jan 1;46(1):120-8
references.pmid: 18171227
references.citation: Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):48-57
references.pmid: 16369093
references.citation: Lipids. 2008 Dec;43(12):1117-25
references.pmid: 18769951
references.citation: Biochim Biophys Acta. 2007 Mar;1770(3):467-77
references.pmid: 16963187
references.citation: Mol Cell Endocrinol. 2004 Feb 27;215(1-2):165-70
references.pmid: 15026190
references.citation: Science. 2011 Aug 19;333(6045):933-5
references.pmid: 21852468
references.citation: Curr Top Med Chem. 2011;11(16):2060-71
references.pmid: 21619513
references.citation: Antimicrob Agents Chemother. 1988 Aug;32(8):1237-42
references.pmid: 3056256
references.citation: J Lipid Res. 2012 Feb;53(2):311-20
references.pmid: 22135275
references.citation: N Engl J Med. 1974 Feb 7;290(6):320-3
references.pmid: 4588286
references.citation: Am J Trop Med Hyg. 1998 Jul;59(1):133-8
references.pmid: 9684641
references.citation: J Med Chem. 2009 May 14;52(9):2846-53
references.pmid: 19354253
references.citation: Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1411-29
references.pmid: 21995615
references.citation: J Med Chem. 2005 Aug 25;48(17):5415-8
references.pmid: 16107140
references.citation: Clin Microbiol Infect. 2004 Mar;10 Suppl 1:1-10
references.pmid: 14748798